Drug Trial Radar · NCT07044271
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jul 11, 2025
Primary completion
Nov 8, 2025
Study completion Nov 8, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to measure how much olomorasib gets into the bloodstream and how long it takes the body to get rid of it. Healthy participants will take olomorasib by mouth. The study will last about 7 weeks and will include 10 back-to-back overnight stays in the research center.
Conditions
- Healthy
Interventions
OlomorasibDrug
Single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Time t (AUC[0-tlast]) of OlomorasibTime frame: From Day 1, Predose up to 72 hours Postdose
- PK: Area Under the Concentration versus Time Curve from Zero to Infinity (AUC[0-∞]) of OlomorasibTime frame: From Day 1, Predose up to 72 hours Postdose
- PK: Maximum Observed Drug Concentration (Cmax) of OlomorasibTime frame: From Day 1, Predose up to 72 hours Postdose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
ICON Early Phase Services
San Antonio, Texas
ICON
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.